Fingolimod
- PDF / 169,198 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 52 Downloads / 155 Views
1 S
Lymphopenia, macular oedema and urinary tract infection: 4 case reports In a descriptive, observational, retrospective study of 55 adult patients who received fingolimod for relapsing-remitting multiple sclerosis between January 2015 and February 2017 or up to treatment suspension, 4 adult patients [exact ages not stated; sexes not stated] were described, who developed lymphopenia, macular oedema or urinary tract infection during treatment with fingolimod for relapsing-remitting multiple sclerosis. The patients, who had relapsing-remitting multiple sclerosis, started receiving fingolimod [dosages and routes not stated]. However, fingolimod was stopped after 2–11 months due to lymphopenia (2 patients), macular oedema (1 patient) and urinary tract infection (1 patient) [time to reactions onsets and outcomes not stated]. Bargiela NF, et al. Fingolimod in multiple sclerosis: Profile of use in habitual practice. European Journal of Hospital Pharmacy 27: 346-349, No. 6, Nov 2020. Available from: 803518547 URL: http://doi.org/10.1136/ejhpharm-2018-001840
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
